Table 2.
Adverse events (n = 156)
| Adverse events | N (%) |
|---|---|
| Eye symptoms | 66 (44.30) |
| Sicca | 36 (23.07) |
| Conjunctivitis | 25 (16.02) |
| Patient-reported | 20 (12.82) |
| Ophthalmologist-diagnosed disease | 5 (3.20) |
| Episcleritis | 3 (1.92) |
| Bacterial conjunctivitis | 1 (0.64) |
| Worsening blepharitis | 1 (0.64) |
| Persistent facial erythema | 10 (6.41) |
| MSK | 6 (3.84) |
| Localised to knees and hip | 1 (0.64) |
| Generalised | 5 (3.20) |
| AA | 5 (3.20) |
| Pre-existing AA | 1 ( 0.64) |
| New onset AA like | 4 (2.56) |
| Patchy AA like | 1(0.64) |
| Diffuse AA like | 1(1.64) |
| Ophiasis pattern | 1(0.64) |
| Drug induced | 1(0.64 |
| Eczema herpeticum | 1 (0.64) |
| Vasovagal episodes | 3 (1.92) |
| Injection site reaction | 2 (1.31) |
| Pneumonia | 1 ( 0.64) |
| Flu-like symptoms | 1 (0.64) |
MSK musculoskeletal, AA alopecia areata